|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heidenreich A, Aus G, Bolla M, Joniau S,
Matveev VB, Schmid HP and Zattoni F: European Association of
Urology: EAU guidelines on prostate cancer. Eur Urol. 53:68–80.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:ra82014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kong D, Banerjee S, Ahmad A, Li Y, Wang Z,
Sethi S and Sarkar FH: Epithelial to mesenchymal transition is
mechanistically linked with stem cell signatures in prostate cancer
cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nauseef JT and Henry MD:
Epithelial-to-mesenchymal transition in prostate cancer: Paradigm
or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
7
|
Rabbani SA, Arakelian A and Farookhi R:
LRP5 knockdown: Effect on prostate cancer invasion growth and
skeletal metastasis in vitro and in vivo. Cancer Med. 2:625–635.
2013.PubMed/NCBI
|
|
8
|
Dai J, Hall CL, Escara-Wilke J, Mizokami
A, Keller JM and Keller ET: Prostate cancer induces bone metastasis
through Wnt-induced bone morphogenetic protein-dependent and
independent mechanisms. Cancer Res. 68:5785–5794. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun JY, Zhong Y, Yin JT, Liu L, Wang B and
Zuo CX: Isolation and structure identification of triterpenoids
from Gypsophila oldhamiana. Chin Trad Herbal Drugs.
36:644–646. 2005.
|
|
10
|
Wang FL, Sun JY, Wang Y, Mu YL, Liang YJ,
Chong ZZ, Qin SH and Yao QQ: Oldhamianoside II, a new
triterpenoidsaponin, prevents tumor growth via inducing cell
apoptosis and inhibiting angiogenesis. Oncol Res. 20:369–376. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Zhang J, Yang X, Chang YW, Qi M,
Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis
in prostate cancer and promotes epithelial-mesenchymal transition
in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Zheng Y, Xu H, Yan X and Chang X:
Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis.
PLoS One. 8:e533012013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Li Y, Yang X, Yuan H, Li X, Qi M,
Chang YW, Wang C, Fu W, Yang M, et al: ERG-SOX4 interaction
promotes epithelial-mesenchymal transition in prostate cancer
cells. Prostate. 74:647–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smith BN and Odero-Marah VA: The role of
Snail in prostate cancer. Cell Adh Migr. 6:433–441. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:29–26. 2009. View Article : Google Scholar
|
|
17
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fischer JA: Deubiquitinating enzymes:
Their roles in development, differentiation, and disease. Int Rev
Cytol. 229:43–72. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koch A, Waha A, Hartmann W, Hrychyk A,
Schüller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D and
Pietsch T: Elevated expression of Wnt antagonists is a common event
in hepatoblastomas. Clin Cancer Res. 11:4295–4304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bullions LC and Levine AJ: The role of
beta-cateninin cell adhesion, signal transduction, and cancer. Curr
Opin Oncol. 10:81–87. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mulholland DJ, Dedhar S, Coetzee GA and
Nelson CC: Interaction of nuclear receptors with the
Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr
Rev. 26:898–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sundram V, Chauhan SC, Ebeling M and Jaggi
M: Curcumin attenuates β-catenin signaling in prostate cancer cells
through activation of protein kinase D1. PLoS One. 7:e353682012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yokoyama NN, Shao S, Hoang BH, Mercola D
and Zi X: Wnt signaling in castration-resistant prostate cancer:
Implications for therapy. Am J Clin Exp Urol. 15:27–44. 2014.
|
|
26
|
Park JH, Kwon HY, Sohn EJ, Kim KA, Kim B,
Jeong SJ, Song JH, Koo JS and Kim SH: Inhibition of Wnt/β-catenin
signaling mediates ursolic acid-induced apoptosis in PC-3 prostate
cancer cells. Pharmacol Rep. 65:1366–1374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robinson DR, Zylstra CR and Williams BO:
Wnt signaling and prostate cancer. Curr Drug Targets. 9:571–580.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kypta RM and Waxman J: Wnt/β-catenin
signaling in prostate cancer. Nat Rev Urol. 9:418–428. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kagey MH and He X: Rationale for targeting
the Wnt signalling modulator Dickkopf-1 for oncology. Br J
Pharmacol. 174:4637–4650. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS,
Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, et al: EZH2-mediated
concordant repression of Wnt antagonists promotes
β-catenin-dependent hepatocarcinogenesis. Cancer Res. 71:4028–4039.
2011. View Article : Google Scholar : PubMed/NCBI
|
